Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

2.780
-0.070-2.46%
Volume:3.32M
Turnover:8.93M
Market Cap:1.71B
PE:191.62
High:2.895
Open:2.895
Low:2.565
Close:2.850
52wk High:15.960
52wk Low:2.565
Shares:614.00M
HK Float Shares:614.00M
Volume Ratio:0.54
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.015
ROE:-4.11%
ROA:-1.28%
PB:0.55
PE(LYR):191.62
PS:2.34

Loading ...

Boan Biotech: No Share Capital Changes in May; Public Float Remains Above 18.14% Waiver Threshold

Bulletin Express
·
Jun 03

BOAN BIOTECH Submits US Applications for Two Denosumab Biosimilars

Stock News
·
May 29

Shandong Boan Bio submits US FDA BLA for two denosumab biosimilars

Reuters
·
May 29

Shandong Boan Biotechnology Co Ltd - Bla Submission for Two Denosumab Biosimilars in U.S. to FDA

THOMSON REUTERS
·
May 29

Shandong Boan Biotechnology Co Ltd - Ba6101 Obtained Marketing Approved in Bolivia

THOMSON REUTERS
·
May 29

BOAN BIOTECH Sets 22 June 2026 AGM; Seeks Fresh Share Mandates and Launches 2% RSU Plan

Bulletin Express
·
May 27

BOAN BIOTECH Sets 22 June 2026 AGM; Seeks 20% Share Issuance Mandate, 10% Buy-Back Authority and RSU Scheme Approval

Bulletin Express
·
May 27

Shandong Boan Biotechnology announces annual shareholder meeting

Reuters
·
May 27

Shandong Boan Biotechnology Says Boluojia (Denosumab Injection) Approved By NMPA

Reuters
·
May 26

BOAN BIOTECH's Denosumab Injection BOLUOGA® Gains New Indication Approval in China

Stock News
·
May 26

Shandong Boan says China regulator approves expanded Boluojia use for bone metastases, multiple myeloma

Reuters
·
May 26

Shandong Boan Biotechnology Co Ltd - Boluojia (Denosumab Injection) Approved in China for Bone Metastases by Nmpa

THOMSON REUTERS
·
May 26

Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval

Stock Track
·
May 19

BOAN BIOTECH Shares Surge on Share Buyback Plan and New Drug Approval in Macau

Stock News
·
May 19

Boan Biotechnology Announces HK$200 Million Share Buyback

MT Newswires Live
·
May 14

Boan Biotech Announces Plan for On-Market Share Repurchase of up to HK$200 Million

Bulletin Express
·
May 13

Shandong Boan Biotechnology launches share buyback program worth up to HK$ 200 million

Reuters
·
May 13

Shandong Boan Biotechnology Co Ltd - to Repurchase Shares up to HK$200 Mln

THOMSON REUTERS
·
May 13

Boan Biotech Maintains 622.33 Million Issued Shares and Meets Public‐Float Requirement in April 2026

Bulletin Express
·
May 07

BOAN BIOTECH's Stock Plummets Nearly 70% in Eight Months, Faces Critical Test to Maintain Stock Connect Eligibility

Stock News
·
May 01